Opdivo nivolumab: Phase II data

Data from 80 evaluable patients with classical Hodgkin’s lymphoma who received Adcetris brentuximab vedotin after a failed autologous stem cell transplantation (ASCT) in the open-label, international Phase II

Read the full 284 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE